On July 14, 2020 the New England Journal of Medicine published the preliminary report of the results from the phase 1 trials of Moderna’s vaccine for COVID-19. Despite an extremely high percentage of Moderate to Severe adverse events after the second dose, the group’s conclusion was that “no trial-limiting safety concerns were identified. These findings support further development of this vaccine.”

The following was written by the West Virginians for Health Freedom group and sent to all West Virginia’s legislators.

Dear Legislator,

  • The results of Moderna’s phase 1 vaccine trial for COVID-19 were published online Tuesday in the NEJM.
  • 80% of healthy subjects (avg age 33 years old) in the 100 mcg and 250 mcg dose groups had moderate to severe adverse events after the 2nd vaccination.